ClinicalTrials.gg

Program

ontamalimab

Also written as “Ontamalimab”, “PF-00547659 SC Injection” and “PF-00547659 SC injection”.

Its studies are mostly in Crohn Disease · Colitis, Ulcerative · Fatty Liver, led by Takeda.

Furthest: phase 3, since Aug 21, 201712 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda120 open or runningphase 3since Aug 21, 2017Jan 12, 2011none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 12, 2011First studies: 2 phase 2 studies in Crohn DiseaseFirst studyNCT01276509, NCT01298492
  2. Jun 13, 2012Phase 2 study in Colitis, UlcerativeNCT01620255 · 357 enrolled · United States, Australia, Austria and more
  3. Jan 8, 2013Phase 2 study in Colitis, UlcerativeNCT01771809 · 330 enrolled · United States, Australia, Austria and more
  4. Aug 21, 20172 phase 3 studies in Colitis, UlcerativeNCT03259334, NCT03259308
  5. Sep 6, 20172 phase 3 studiesNCT03290781, NCT03283085
  6. May 9, 20182 phase 3 studies in Crohn DiseaseNCT03566823, NCT03559517
  7. Jul 24, 2018Phase 3 study in Crohn DiseaseNCT03627091 · 40 enrolled · United States, Argentina, Australia and more
  8. Jun 30, 2025Phase 1 study in Fatty LiverNCT07052682 · 11 enrolled · United States

TargetBeta

MADCAM1 →read by rule
“Mucosal addressin cell adhesion molecule-1 inhibitor”ChEMBL 37, by rule

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07052682Fatty Liver · United States1TerminatedDec 30, 202411
NCT03627091Crohn Disease · United States, Argentina, Australia and more3TerminatedJun 21, 202140
NCT03566823Crohn Disease · United States, Argentina, Belgium and more3TerminatedAug 18, 202034
NCT03559517Crohn Disease · United States, Australia, Austria and more3TerminatedJul 7, 202030
NCT03283085Crohn Disease · United States, Argentina, Australia and more3CompletedDec 13, 2023557
NCT03290781Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedJul 1, 2021366
NCT03259334Colitis, Ulcerative · United States, Australia, Austria and more3TerminatedJul 22, 2020380
NCT03259308Colitis, Ulcerative · United States, Argentina, Belgium and more3TerminatedJul 15, 2020279
NCT01771809Colitis, Ulcerative · United States, Australia, Austria and more2CompletedDec 13, 2017330
NCT01620255Colitis, Ulcerative · United States, Australia, Austria and more2CompletedSep 22, 2014357
NCT01298492Crohn Disease · United States, Austria, Belgium and more2CompletedJul 27, 2016268
NCT01276509Crohn Disease · United States, Austria, Belgium and more2CompletedFeb 7, 2014265

How it is read

Names in the registry

  • “Ontamalimab”, 7 entries
  • “PF-00547659 SC Injection”, 4 entries
  • “PF-00547659 SC injection”, 4 entries
  • “25 mg Ontamalimab”, 1 entry
  • “75 mg Ontamalimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.